KR870700024A - Preparations for intramuscular injection of drugs, vitamins or waxes - Google Patents

Preparations for intramuscular injection of drugs, vitamins or waxes

Info

Publication number
KR870700024A
KR870700024A KR1019860700540A KR860700540A KR870700024A KR 870700024 A KR870700024 A KR 870700024A KR 1019860700540 A KR1019860700540 A KR 1019860700540A KR 860700540 A KR860700540 A KR 860700540A KR 870700024 A KR870700024 A KR 870700024A
Authority
KR
South Korea
Prior art keywords
salts
racemic
type
glucoheptonate
solution
Prior art date
Application number
KR1019860700540A
Other languages
Korean (ko)
Inventor
파루크 닥터 핫지젤리모빅
Original Assignee
원본미기재
메파 악티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 메파 악티엔 게젤샤프트 filed Critical 원본미기재
Publication of KR870700024A publication Critical patent/KR870700024A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

The addition of pharmaceutically accepted hydrosoluble organic or inorganic calcium salts, particularly calcium glucoheptonate to a drug, vitamin or vaccine to be administered by intramuscular injection enables to obtain a painless injection without adding local anaesthetics.

Description

약, 비타민 또는 왁진의 근육내 주사용 제제Preparations for intramuscular injection of drugs, vitamins or waxes

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (8)

유기 또는 무기산의 수용성 칼슘염, 특히 라세미형태, D-형 또는 L-형의 Ca 글루코헵토네이트를 함유하는, 약, 비타민, 또는 왁진의 근육내 주사용 제제.A preparation for intramuscular injection of drugs, vitamins, or waxes containing water-soluble calcium salts of organic or inorganic acids, in particular racemic, D- or L-type Ca glucoheptonate. 유기 또는 무기산의 수용성 Ca 염, 특히 라세미형태, D-형 또는 L형의 Ca 글루코헵토네이트를 근육내 무통(無痛)주사에 의해 투여할 수 있는 제제를 만들기 위해 사용하는 용도.Use of water-soluble Ca salts of organic or inorganic acids, in particular racemic, D- or L-type Ca glucoheptonate, to make formulations which can be administered by intramuscular painless injection. 제1항 또는 2항에 있어서 Ca염으로서 황산칼슘, 락토비온산, 레블린산 또는 락트산의 Ca 염, 또는 특히 레세미형태, D-형 또는 L-형의 Ca 글루코헵토네이트를 개별적으로 또는 혼합물로서, 약, 비타민 도는 왁진에 가하여 혼합한 제제.The Ca salts according to claim 1 or 2, individually or as a mixture, as Ca salts, Ca salts of lactobionic acid, levulinic acid or lactic acid, or especially Ca glucoheptonates of racemic, D- or L-type. As a medicine, vitamin or wax added and mixed. 제1항 내지 3항중 어느 하나에 있어서, Ca염을 증류 또는 2차 증류시킨 H2O, 생리염용액 또는 5% 글르코스 용액에 용해시킨 용액으로서 약에 가한 제제.The preparation according to any one of claims 1 to 3, wherein the Ca salt is dissolved in H 2 O, distilled or secondary distilled, a physiological salt solution or a 5% glucose solution. 제1항 내지 4항중 어느 하나에 있어서, Ca염을 0.01~25%, 특히 10%의 용매내 농도로써 사용한 제제.The formulation according to any one of claims 1 to 4, wherein the Ca salt is used at a concentration in solvent of 0.01-25%, in particular 10%. 제5항에 있어서, 라세미형태, D-형 또는 L-형인 Ca 글루코헵토네이트 수용액을 사용한 제제.The formulation according to claim 5, wherein the aqueous solution of Ca glucoheptonate is racemic, D- or L-form. 제1항 내기 6항중 어느 하나에 있어서 300,000I.U. 의 페니실린에 대하여 0.5~2.5ml, 특히 1~1.5ml의 10% Ca 염용액을 가한 제제.300,000 I.U. Formulation to which 0.5-2.5 ml, especially 1-1.5 ml of 10% Ca salt solution was added with respect to the penicillin of. 제7항에 있어서, 라세미형태 D-형, 또는 L-형의 Ca 글루코헵토네이트 용액 1~1.5ml를 가한 제제8. The formulation according to claim 7, wherein 1-1.5 ml of a racemic D-type or L-type Ca glucoheptonate solution is added. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019860700540A 1984-07-12 1985-12-06 Preparations for intramuscular injection of drugs, vitamins or waxes KR870700024A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH5860/84-9 1984-07-12
CH586084 1984-12-07
PCT/CH1985/000172 WO1986003413A1 (en) 1984-12-07 1985-12-06 Preparations for the intramuscular injection of drugs, vitamins or vaccines

Publications (1)

Publication Number Publication Date
KR870700024A true KR870700024A (en) 1987-02-28

Family

ID=4300514

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860700540A KR870700024A (en) 1984-07-12 1985-12-06 Preparations for intramuscular injection of drugs, vitamins or waxes

Country Status (9)

Country Link
EP (1) EP0204737B1 (en)
KR (1) KR870700024A (en)
AT (1) ATE74523T1 (en)
AU (1) AU5198686A (en)
DE (1) DE3585835D1 (en)
DK (1) DK365786D0 (en)
FI (1) FI863192A (en)
NO (1) NO863082D0 (en)
WO (1) WO1986003413A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267962B1 (en) 1990-12-21 2001-07-31 C-P Technology Limited Partnership Compositions and methods of treatment using peat derivatives
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
NO20014746D0 (en) 2001-09-28 2001-09-28 Clas M Kjoelberg Pain reliever
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
WO2006012700A1 (en) * 2004-08-04 2006-02-09 Team Health Pty Ltd Method of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1023821A (en) * 1950-04-21 1953-03-24 Stable solution of calcium gluconate and process for its preparation
DE1007022B (en) * 1953-06-02 1957-04-25 Sandoz Ag Process for improving the shelf life and solubility of antihistamine preparations
DE1062389B (en) * 1958-02-11 1959-07-30 Wander Ag Dr A Process for the preparation of sterile vitamin D solutions containing calcium salts
US4081527A (en) * 1976-12-07 1978-03-28 Pfizer Inc. Chlortetracycline compositions

Also Published As

Publication number Publication date
DE3585835D1 (en) 1992-05-14
FI863192A0 (en) 1986-08-05
EP0204737B1 (en) 1992-04-08
WO1986003413A1 (en) 1986-06-19
AU5198686A (en) 1986-07-01
EP0204737A1 (en) 1986-12-17
NO863082L (en) 1986-07-30
DK365786A (en) 1986-07-31
DK365786D0 (en) 1986-07-31
ATE74523T1 (en) 1992-04-15
FI863192A (en) 1986-08-05
NO863082D0 (en) 1986-07-30

Similar Documents

Publication Publication Date Title
US4153689A (en) Stable insulin preparation for nasal administration
CA2090422C (en) Pharmaceutical composition of florfenicol
EP0072462B1 (en) Pharmaceutical preparations
ATE64297T1 (en) SPRAYABLE PHARMACEUTICAL PREPARATION FOR TOPICAL USE.
KR960000923A (en) Preparation of Monomeric Insulin Analogs
ES2171469T3 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT.
ATE16191T1 (en) STABLE SALTS OF S-ADENOSINYLMETHIONINE, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES AS THE ACTIVE SUBSTANCE.
KR910000703A (en) Antagonists of Tetrazol Stimulating Amino Acid Receptors
DE58901002D1 (en) AGENT WITH DESTROYING EFFECT ON MALIGNE TUMORS, METHOD FOR THE PRODUCTION THEREOF AND PREPARATION FOR USE IN THE THERAPY OF CANCER DISEASES.
US4777047A (en) Transdermal application form of calcium antagonists
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
KR870700024A (en) Preparations for intramuscular injection of drugs, vitamins or waxes
KR880007060A (en) Pharmaceutical composition
ES2052000T3 (en) PROCEDURE FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING PENTAMIDINE.
BR0013283A (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
US4476115A (en) Analgesic composition and method of treating subdermal pain
KR910002451A (en) Agents for topical administration containing methanediphosphonic acid derivatives and uses thereof
JPH03120230A (en) Percutaneous absorbefacient of drug active ingredient and percutaneous absorption type pharmaceutical
US4666926A (en) Transdermal formulations
Newmark et al. Coumermycin a1—biopharmaceutical studies I
KR880012518A (en) Analgesic and anti-inflammatory pharmaceutical compositions containing naphthal-acetic acid derivatives
KR880009943A (en) Pyridazinone derivatives
KR870001144A (en) Pharmaceutical composition containing NN-dimethylethyl oxide and its production method
EP0003382A1 (en) Solvent vehicle for therapeutics and pharmaceutical composition containing it
RU2238086C2 (en) New medicinal formulation of n-(4-nitro-2-phenoxyphenyl)methanesulfonamide, method for its preparing and application

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid